LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma

被引：0
|
作者：
Choueiri, Toni K. [1 ,2 ]
Powles, Thomas [3 ,4 ]
Voss, Martin H. [5 ]
Plimack, Elizabeth R. [6 ]
Gurney, Howard [7 ,8 ]
Song, Yue [9 ]
Perini, Rodolfo F. [9 ]
Rodriguez-Lopez, Karla [9 ]
Rini, Brian, I [10 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Barts Hlth NHS Trust, London, England
[4] Queen Mary Univ London, Royal Free NHS Fdn Trust, Barts Canc Inst, London, England
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Macquarie Univ Hosp, Sydney, NSW, Australia
[9] Merck & Co Inc, Rahway, NJ USA
[10] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
FUTURE ONCOLOGY | 2023年 / 19卷 / 40期
关键词：
clear cell renal cell carcinoma; CTLA-4; inhibitor; HIF-2 alpha inhibitor; immune checkpoint inhibitor; PD-1/L1; VEGFR-TKI; NIVOLUMAB; SUNITINIB; CANCER; CABOZANTINIB; COMBINATION; EFFICACY; BLOCKADE; SAFETY;
D O I：
10.2217/fon-2023-0283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Combination treatment with immunotherapy agents and/or vascular endothelial growth factor tyrosine kinase inhibitors are a standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). Novel therapeutic combinations that include the hypoxia-inducible factor 2 alpha inhibitor belzutifan and the cytotoxic T-lymphocyte-associated protein 4 inhibitor quavonlimab are being investigated for their potential to further improve patient outcomes. This protocol describes the rationale and design of the randomized, phase III LITESPARK-012 study, which will evaluate the efficacy and safety of pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab as first-line treatment for advanced ccRCC. Results from this study may support triplet combination therapies as a potential new standard of care for advanced ccRCC.
引用
收藏
页码：2631 / 2640
页数：10
相关论文
共 50 条
  • [31] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [32] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003
    McDermott, D. F.
    Choueiri, T. K.
    Tykodi, S.
    Merchan, J.
    Roy, A.
    Perini, R.
    Vickery, D.
    Bauer, T.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1208 - +
  • [34] Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
    Motzer, Robert
    George, Saby
    Merchan, Jaime R.
    Hutson, Thomas E.
    Song, Xun
    Perini, Rodolfo F.
    Xie, Ran
    Bapat, Urmi
    Puente, Javier
    [J]. ONCOLOGIST, 2023, 28 (06): : 501 - 509
  • [35] Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003
    Choueiri, T. K.
    Bauer, T.
    Merchan, J.
    Figlin, R.
    Roy, A.
    Perini, R.
    Vickery, D.
    Arrowsmith, E.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [36] Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
    Santoni, Matteo
    Rizzo, Alessandro
    Mollica, Veronica
    Rosellini, Matteo
    Marchetti, Andrea
    Fragomeno, Benedetta
    Battelli, Nicola
    Massari, Francesco
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 45 - 51
  • [37] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael S.
    Wolf, Ido
    Fakih, Marwan
    de Vos-Geelen, Judith
    Lee, Valerie
    Vogel, Arndt
    Wu, Xi Lawrence
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
    Haro-Silerio, Jaime Ivan
    Johns, Andrew
    Moussa, Mohammad Jad
    Wang, Mindy
    Wang, Emily
    Kovitz, Craig A.
    Campbell, Matthew T.
    Jonasch, Eric
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
  • [40] Randomized, open-label, 3-arm phase III study comparing MK-1308A+lenvatinib and pembrolizumab (pembro) plus belzutifan plus lenvatinib versus pembro plus lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
    Rini, B. I.
    Plimack, E. R.
    Powles, T. B.
    Voss, M. H.
    Gurney, H. P.
    Silverman, R.
    Perini, R.
    Rodriguez-Lopez, K.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S722 - S723
12345